News & Updates
Filter by Specialty:
Overweight, obesity during pregnancy up offspring’s NAFLD risk
Overweight or obesity during pregnancy increases the risk of future nonalcoholic fatty liver disease (NAFLD) in the offspring, a recent Sweden study has found.
Overweight, obesity during pregnancy up offspring’s NAFLD risk
27 Oct 2021
Novel score predicts survival, radiological response in HCC
The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.
Novel score predicts survival, radiological response in HCC
24 Oct 2021
Environmental contaminants impair liver metabolism, leading to NAFLD
Exposure to environmental contaminants, particularly perfluorinated alkyl substances, seems to disrupt bile acid and lipid metabolism, both key hepatic metabolic pathways that are known to be dysregulated in nonalcoholic fatty liver disease (NAFLD), a recent study has found. Such an effect seems to be more pronounced in women.
Environmental contaminants impair liver metabolism, leading to NAFLD
24 Oct 2021
Fructose from fruit juice, SSBs tied to higher liver fat content
The consumption of fructose from fruit juice and sugar sweetened beverages (SSBs), but not from fruit, is associated with higher intrahepatic lipid (IHL) content, according to data from a cross-sectional study presented at EASD 2021.
Fructose from fruit juice, SSBs tied to higher liver fat content
13 Oct 2021
Gene mutations may provide clues for liver cancer survival
Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.
Gene mutations may provide clues for liver cancer survival
13 Oct 2021
Novel drug helps lessen liver stiffness in high-risk NAFLD
Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.